Insights into pregnancy-related safety outcomes following ravulizumab exposure using real-world data from post-marketing surveillance.
Release Date: June 18, 2026
Reference: Carrillo Infante C, Sherrard H, Williams C, Mujeebuddin A. Pregnancy outcomes following ravulizumab exposure: a pharmacovigilance analysis. Poster TH-P01018 presented at ASN Kidney Week 2025; November 5-9, 2025; Houston, Texas, USA.
Release Date: June 18, 2026
Reference: Carrillo Infante C, Sherrard H, Williams C, Mujeebuddin A. Pregnancy outcomes following ravulizumab exposure: a pharmacovigilance analysis. Poster TH-P01018 presented at ASN Kidney Week 2025; November 5-9, 2025; Houston, Texas, USA.
How common are meningococcal infections in patients receiving C5 inhibitor therapies
like eculizumab and ravulizumab?
This podcast unpacks the latest clinical trial and pharmacovigilance evidence.
Release Date: August 21, 2026
Reference: Carrillo Infante C, Mujeebuddin A. Eculizumab and ravulizumab clinical trial and real-world pharmacovigilance of meningococcal infections across indications. PLoS One. 2025;20(9):e0332073. doi:10.1371/journal.pone.0332073
This podcast unpacks the latest clinical trial and pharmacovigilance evidence.
Release Date: August 21, 2026
Reference: Carrillo Infante C, Mujeebuddin A. Eculizumab and ravulizumab clinical trial and real-world pharmacovigilance of meningococcal infections across indications. PLoS One. 2025;20(9):e0332073. doi:10.1371/journal.pone.0332073
An overview of a recent publication on atypical hemolytic uremic syndrome in adults and current perspectives on treatment and individualized management
Release Date: August 21, 2026
Reference: Ávila A, Cao M, Espinosa M, Manrique J, Morales E. Recommendations for the individualised management of atypical hemolytic uremic syndrome in adults. Front Med. 2023;10:1264310. doi:10.3389/fmed.2023.1264310
Release Date: August 21, 2026
Reference: Ávila A, Cao M, Espinosa M, Manrique J, Morales E. Recommendations for the individualised management of atypical hemolytic uremic syndrome in adults. Front Med. 2023;10:1264310. doi:10.3389/fmed.2023.1264310
Insights into pregnancy-related safety outcomes following ravulizumab exposure using real-world data from post-marketing surveillance.
Release Date: June 18, 2026
Reference: Carrillo Infante C, Sherrard H, Williams C, Mujeebuddin A. Pregnancy outcomes following ravulizumab exposure: a pharmacovigilance analysis. Poster TH-P01018 presented at ASN Kidney Week 2025; November 5-9, 2025; Houston, Texas, USA.
Release Date: June 18, 2026
Reference: Carrillo Infante C, Sherrard H, Williams C, Mujeebuddin A. Pregnancy outcomes following ravulizumab exposure: a pharmacovigilance analysis. Poster TH-P01018 presented at ASN Kidney Week 2025; November 5-9, 2025; Houston, Texas, USA.
How common are meningococcal infections in patients receiving C5 inhibitor therapies
like eculizumab and ravulizumab?
This podcast unpacks the latest clinical trial and pharmacovigilance evidence.
Release Date: August 21, 2026
Reference: Carrillo Infante C, Mujeebuddin A. Eculizumab and ravulizumab clinical trial and real-world pharmacovigilance of meningococcal infections across indications. PLoS One. 2025;20(9):e0332073. doi:10.1371/journal.pone.0332073
Release Date: August 21, 2026
Reference: Carrillo Infante C, Mujeebuddin A. Eculizumab and ravulizumab clinical trial and real-world pharmacovigilance of meningococcal infections across indications. PLoS One. 2025;20(9):e0332073. doi:10.1371/journal.pone.0332073